Key Insights

Highlights

Success Rate

95% trial completion (above average)

Published Results

12 trials with published results (24%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

3.9%

2 terminated out of 51 trials

Success Rate

94.9%

+8.4% vs benchmark

Late-Stage Pipeline

25%

13 trials in Phase 3/4

Results Transparency

32%

12 of 37 completed with results

Key Signals

12 with results95% success

Data Visualizations

Phase Distribution

48Total
Not Applicable (20)
Early P 1 (1)
P 1 (3)
P 2 (11)
P 3 (6)
P 4 (7)

Trial Status

Completed37
Unknown5
Withdrawn3
Terminated2
Recruiting2
Enrolling By Invitation1

Trial Success Rate

94.9%

Benchmark: 86.5%

Based on 37 completed trials

Clinical Trials (51)

Showing 20 of 20 trials
NCT03729271Phase 4Completed

Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea

NCT06153420Phase 2TerminatedPrimary

Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).

NCT04830410Not ApplicableCompletedPrimary

The Effects of Carbohydrates in Irritable Bowel Syndrome

NCT07103772Not ApplicableEnrolling By Invitation

Effect of Consuming a Nutraceutical Composition on Signs and Symptoms in Adult Patients With Irritable Bowel Syndrome

NCT05453916Phase 1WithdrawnPrimary

Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipation

NCT06432569Not ApplicableCompletedPrimary

Evaluation of Butyrate and Palmitoylethanolamide in IBS Patients (B/P3_1)

NCT06543498Not ApplicableCompletedPrimary

The Effect of Dietary Supplementation on Intestinal Barrier Function in IBS-D

NCT04214470Withdrawn

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in IBS

NCT04806386Not ApplicableCompleted

The Role of Fiber in the Prevention and Treatment of Fecal Incontinence

NCT06247046Phase 3RecruitingPrimary

A Study to Evaluate the Efficacy and Safety of Live SK08 Powder in Patients With IBS-D

NCT05754177Not ApplicableCompletedPrimary

Safety and Efficacy of a Probiotic Supplement in IBS-D

NCT04855799Phase 2Completed

GI Permeability Change in Response to Aquamin®

NCT06612411Early Phase 1RecruitingPrimary

B.Subtilis Attenuate Symptoms in Diarrhea-predominant Irritable Bowel Syndrome by Increasing Hypoxanthine Biosynthesis

NCT04492787Phase 2CompletedPrimary

Efficacy and Safety of Changkang Granule in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

NCT03806959Not ApplicableCompletedPrimary

Interest of Pan Capsule in Symptomatic Patients Suspected of Irritable Bowel Syndrome Requiring Colonoscopy

NCT06297421Phase 2Not Yet RecruitingPrimary

Efficacy and Safety of FMT for the Treatment of IBS-D and Mental Health Comorbidity in Young Adults

NCT04899869Not ApplicableCompletedPrimary

Faecal Microbiota Transplantation in Irritable Bowel Syndrome

NCT05702255Not ApplicableCompletedPrimary

Self- Administered Acupressure for Diarrhea Predominant Irritable Bowel Syndrome

NCT05130047Phase 2Completed

Aldafermin (NGM282) for Chronic Diarrhea Due to Bile Acid Malabsorption (BAM)

NCT05339243Not ApplicableCompletedPrimary

Evaluating the Safety and Efficacy of the Probiotic Bifidobacterium Longum ES1 and the Post Biotic Heat-treated Bifidobacterium Longum ES1 (HT-ES1) on IBS Symptom Severity in Patients With Diarrhoea Predominant Irritable Bowel Syndrome

Scroll to load more

Research Network

Activity Timeline